Shionogi signs agreement to supply Covid-19 oral antiviral to Japan
Shionogi & Co has signed an agreement with the Japanese Ministry of Health, Labor and Welfare (MHLW) to deliver courses of the oral antiviral drug S-217622, for Covid-19, in the country. An inhibitor of 3CL protease, S-217622 was developed under the joint research of Shionogi with Hokkaido University, in Japan. 3CL protease is vital for…
Read More